139 related articles for article (PubMed ID: 8299084)
1. Evaluation of melanin-related metabolites as markers of melanoma progression.
Horikoshi T; Ito S; Wakamatsu K; Onodera H; Eguchi H
Cancer; 1994 Feb; 73(3):629-36. PubMed ID: 8299084
[TBL] [Abstract][Full Text] [Related]
2. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression.
Horikoshi T; Ito S
J Dermatol; 1992 Nov; 19(11):809-13. PubMed ID: 1293168
[TBL] [Abstract][Full Text] [Related]
3. Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice.
Wakamatsu K; Ito S; Fujita K
Acta Derm Venereol; 1990; 70(5):367-72. PubMed ID: 1980967
[TBL] [Abstract][Full Text] [Related]
4. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid, biochemical markers of melanoma progression.
Wakamatsu K; Ito S; Horikoshi T
Melanoma Res; 1991; 1(2):141-7. PubMed ID: 1823626
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience.
Wakamatsu K; Kageshita T; Furue M; Hatta N; Kiyohara Y; Nakayama J; Ono T; Saida T; Takata M; Tsuchida T; Uhara H; Yamamoto A; Yamazaki N; Naito A; Ito S
Melanoma Res; 2002 Jun; 12(3):245-53. PubMed ID: 12140381
[TBL] [Abstract][Full Text] [Related]
6. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
[TBL] [Abstract][Full Text] [Related]
7. Serum concentration of 5-S-cysteinyldopa in patients with melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Fejös Z; Horváth B; Liszkay G; Beczássy E; Kremmer T
Eur J Clin Invest; 2000 Oct; 30(10):900-4. PubMed ID: 11029605
[TBL] [Abstract][Full Text] [Related]
8. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.
Kärnell R; von Schoultz E; Hansson LO; Nilsson B; Arstrand K; Kågedal B
Melanoma Res; 1997 Oct; 7(5):393-9. PubMed ID: 9429222
[TBL] [Abstract][Full Text] [Related]
9. Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese.
Wakamatsu K; Ito S
Pigment Cell Res; 1995 Jun; 8(3):132-4. PubMed ID: 7567788
[TBL] [Abstract][Full Text] [Related]
10. Determination of eumelanin in human urine.
Wakamatsu K; Takasaki A; Kågedal B; Kageshita T; Ito S
Pigment Cell Res; 2006 Apr; 19(2):163-9. PubMed ID: 16524432
[TBL] [Abstract][Full Text] [Related]
11. 5-S-cysteinyldopa in urine and tumors.
Hara H; Chino K; Kawanami T; Sameshima T; Morishima T
J Dermatol; 1992 Nov; 19(11):806-8. PubMed ID: 1293167
[TBL] [Abstract][Full Text] [Related]
12. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases.
Yamada K; Walsh N; Hara H; Jimbow K; Chen H; Ito S
Arch Dermatol; 1992 Apr; 128(4):491-4. PubMed ID: 1580656
[TBL] [Abstract][Full Text] [Related]
13. High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma.
Hara H; Walsh N; Yamada K; Jimbow K
J Invest Dermatol; 1994 Apr; 102(4):501-5. PubMed ID: 8151128
[TBL] [Abstract][Full Text] [Related]
14. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.
Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M
Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180
[TBL] [Abstract][Full Text] [Related]
15. Melanin-related metabolites in urine of B16 melanoma-bearing mice.
Wakamatsu K; Ito S; Fujita K
Acta Derm Venereol; 1988; 68(5):385-9. PubMed ID: 2461020
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T; Ottó S
Pathol Oncol Res; 1999; 5(3):218-22. PubMed ID: 10491021
[TBL] [Abstract][Full Text] [Related]
17. [5-S-cysteinyldopa as a tumor marker for primary uveal malignant melanoma].
Goto H; Tenou T; Kudo H; Iwasaki T; Muramatsu R; Usui M; Wakamatsu K; Ito S
Nippon Ganka Gakkai Zasshi; 1998 May; 102(5):319-26. PubMed ID: 9619024
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of melanin-related metabolites as markers of solar ultraviolet-B radiation.
Wakamatsu K; Ito S
Pigment Cell Res; 2006 Oct; 19(5):460-4. PubMed ID: 16965276
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
20. A method for measuring serum levels of melanin-associated indole metabolites using LC-MS/MS and its application to malignant melanoma.
Takiwaki M; Umemura H; Kikutani Y; Fukuzawa S; Abe K; Fujino K; Sugihara S; Tachibana K; Morizane S; Satoh M; Nakayama T; Yamasaki O
Clin Chim Acta; 2024 Apr; 557():117873. PubMed ID: 38493943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]